Microbot Medical Inc.
MBOTNasdaq
$1.75
↓ -2.2%Jul 17 close · end-of-day
Price
1Y↓ -31.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$117.5M
Enterprise Value
$45.0M
P/E
—
P/S
—
P/B
1.6
EV/EBITDA
—
PEG
—
FCF Yield
-13.1%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$14.2M
Free Cash Flow (TTM)
-$15.4M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-19.2%
ROIC
-789.6%
Debt / Equity
—
Net Cash
$72.5M
Return 1Y
-30.6%
Company profile
Microbot Medical Inc. engages in the research, design, and development of robotic endoluminal surgery devices. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation.
- CEO
- Harel Gadot
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 20
- Headquarters
- Massachusetts
- Website
- www.microbotmedical.com
Earnings
MBOT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$105,000.00—
Diluted EPS-$0.05↓ -37.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.1M | -$11.4M | -$13.3M | -$9.9M | -$11.6M | -$14.7M |
| Net income | -$9.2M | -$11.3M | -$13.2M | -$10.7M | -$11.4M | -$13.1M |
| Diluted EPS | — | — | -$1.81 | -$1.05 | -$0.73 | -$0.29 |
| Operating cash flow | -$7.3M | -$9.4M | -$11.5M | -$8.5M | -$8.8M | -$13.0M |
| Free cash flow | -$7.3M | -$9.4M | -$11.6M | -$8.6M | -$8.9M | -$13.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $105,000.00 |
| Gross profit | — | — | — | — | — | — | — | $2,000.00 |
| Operating income | -$2.5M | -$3.3M | -$3.4M | -$3.0M | -$3.7M | -$3.9M | -$4.1M | -$4.3M |
| Net income | -$2.5M | -$3.2M | -$3.4M | -$2.6M | -$3.5M | -$3.6M | -$3.5M | -$3.7M |
| Diluted EPS | -$0.17 | -$0.20 | -$0.19 | -$0.08 | -$0.10 | -$0.07 | -$0.04 | -$0.05 |
| Operating cash flow | -$2.0M | -$2.8M | -$1.7M | -$2.9M | -$2.6M | -$3.8M | -$3.8M | -$5.1M |
| Free cash flow | -$2.0M | -$2.8M | -$1.7M | -$2.9M | -$2.6M | -$3.9M | -$3.8M | -$5.2M |
| Gross margin | — | — | — | — | — | — | — | 1.9% |
| Operating margin | — | — | — | — | — | — | — | -4114.3% |
| Net margin | — | — | — | — | — | — | — | -3496.2% |
Company news
Jun 30, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.